Acutely dysregulated, chronically disabled by the enemy within: T-cell responses to HIV-1 infection

Immunology and Cell Biology

Volumn 85, Issue 1, 2007, Pages 6-15

  Munier, M L ^a,b   Kelleher, A D ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

AIDS; Human immunodeficiency virus; Immunity cellular; T cell

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; KI 67 ANTIGEN; PERFORIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN SPECIFICITY; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL REGENERATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE RESPONSE; LYMPHOID ORGAN; MEMORY CELL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ANTIGENS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HIV INFECTIONS; HIV-1; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33846034122     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100015     Document Type: Review

References (159)

1. Cooper DA, Tindall B, Wilson EJ, Imrie AA, Penny R. Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. J Infect Dis 1988; 157: 889-896.
2. Kaufmann GR, Cunningham P, Kelleher AD, Zaunders J, Carr A, Vizzard J et al. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis 1998; 178: 1812-1815.
3. Mellors JW, Kingsley LA, Rinaldo Jr CR, Todd JA, Hoo BS, Kokka RP et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
4. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
5. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-969.
6. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P et al. Characteristics, determinants, and clinical relevance of CD4T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41: 361-372.
7. Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999; 180: 320-329.
8. Aiuti F, Mezzaroma I. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006; 8: 88-97.
9. De Martini RM, Turner RR, Formenti SC, Boone DC, Bishop PC, Levine AM et al. Peripheral blood mononuclear cell abnormalities and their relationship to clinical course in homosexual men with HIV infection. Clin Immunol Immunopathol 1988; 46: 258-271.
10. Zaunders J, Carr A, McNally L, Penny R, Cooper DA. Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. AIDS 1995; 9: 561-566.
11. Ullum H, Lepri AC, Victor J, Skinhoj P, Phillips AN, Pedersen BK. Increased losses of CD4+CD45RA+ cells in late stages of HIV infection is related to increased risk of death: evidence from a cohort of 347 HIV-infected individuals. AIDS 1997; 11: 1479-1485.
12. Schnittman SM, Lane HC, Greenhouse J, Justment JS, Baseler M, Fauci AS. Preferential infection of CD4+ memory T cells by human immunodeficency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990; 87: 6058-6062.
13. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
14. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-666.
15. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71: 7478-7487.
16. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94: 1925-1930.
17. Murray JM, Kaufmann G, Kelleher AD, Cooper DA. A model of primary HIV-1 infection. Math Biosci 1998; 154: 57-85.
18. Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, Katlama C et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998; 4: 215-221.
19. Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3: 533-540.
20. Zinkernagel RM, Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today 1994; 15: 262-268.
21. Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, Paolucci S et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997; 94: 9848-9853.
22. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-1356.
23. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J et al. Increases in CD4 lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection, a preliminary study. N Engl J Med 1995; 332: 567-575.
24. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321-329.
25. Autran B, Carcelain G, Debre P. Immune reconstitution after highly active antiretroviral treatment of HIV infection. Adv Exp Med Biol 2001; 495: 205-212.
26. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
27. Autran B, Carcelaint G, Li TS, Gorochov G, Blanc C, Renaud M et al. Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999; 66: 207-211.
28. Cohen Stuart J, Hamann D, Borleffs J, Roos M, Miedema F, Boucher C et al. Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. AIDS 2002; 16: 2263-2266.
29. Cossarizza A, Poccia F, Agrati C, D'Offizi G, Bugarini R, Pinti M et al. Highly active antiretroviral therapy restores CD4+ Vbeta T-cell repertoire in patients with primary acute HIV infection but not in treatment-naive HIV+ patients with severe chronic infection. J Acquir Immune Defic Syndr 2004; 35: 213-222.
30. Pahwa S, Chitnis V, Mitchell RM, Fernandez S, Chandrasekharan A, Wilson CM et al. CD4+ and CD8+ T cell receptor repertoire perturbations with normal levels of T cell receptor excision circles in HIV-infected, therapy-naive adolescents. AIDS Res Hum Retroviruses 2003; 19: 487-495.
31. Kou ZC, Puhr JS, Wu SS, Goodenow MM, Sleasman JW. Combination antiretroviral therapy results in a rapid increase in T cell receptor variable region beta repertoire diversity within CD45RA CD8T cells in human immunodeficiency virus-infected children. J Infect Dis 2003; 187: 385-397.
32. Kostense S, Raaphorst FM, Joling J, Notermans DW, Prins JM, Danner SA et al. T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy. AIDS 2001; 15: 1097-1107.
33. Gea-Banacloche JC, Martino L, Mican JM, Hallahan CW, Baseler M, Stevens R et al. Longitudinal changes in CD4+ T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients. AIDS Res Hum Retroviruses 2000; 16: 1877-1886.
34. Hazenberg MD, Otto SA, Cohen Stuart JW, Verschuren MC, Borleffs JC, Boucher CA et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000; 6: 1036-1042.
35. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000; 1: 285-289.
36. Kaufmann GR, Zaunders J, Murray J, Kelleher AD, Lewin SR, Solomon A et al. Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. AIDS Res Hum Retroviruses 2001; 17: 147-159.
37. Haynes BF, Hale LP, Weinhold KJ, Patel DD, Liao HX, Bressler PB et al. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest 1999; 103: 921.
38. Sempowski GD, Hicks CB, Eron JJ, Bartlett JA, Hale LP, Ferrari G et al. Naive T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. J Clin Immunol 2005; 25: 462-472.
39. Dion ML, Poulin JF, Bordi R, Sylvestre M, Corsini R, Kettaf N et al. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity 2004; 21: 757-768.
40. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690-695.
41. Markert ML, Alvarez-McLeod AP, Sempowski GD, Hale LP, Horvatinovich JM, Weinhold KJ et al. Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17: 1635-1643.
42. Steffens CM, Smith KY, Landay A, Shott S, Truckenbrod A, Russert M et al. T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals. AIDS 2001; 15: 1757-1764.
43. Sodora DL, Douek DC, Silvestri G, Montgomery L, Rosenzweig M, Igarashi T et al. Quantification of thymic function by measuring T cell receptor excision circles within peripheral blood and lymphoid tissues in monkeys. Eur J Immunol 2000; 30: 1145-1153.
44. McFarland RD, Douek DC, Koup RA, Picker LJ. Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci USA 2000; 97: 4215-4220.
45. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA 2001; 98: 8732.
46. Beq S, Delfraissy JF, Theze J. Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential. Eur Cytokine Netw 2004; 15: 279-289.
47. Kimmig S, Przybylski GK, Schmidt CA, Laurisch K, Mowes B, Radbruch A et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med 2002; 195: 789-794.
48. Ashman LK, Aylett GW. Expression of CD31 epitopes on human lymphocytes: CD31 monoclonal antibodies differentiate between naive (CD45RA+) and memory (CD45RA-) CD4-positive T cells. Tissue Antigens 1991; 38: 208-212.
49. Kalayjian RC, Spritzler J, Pu M, Landay A, Pollard RB, Stocker V et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005; 192: 1577-1587.
50. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001; 7: 73-79.
51. Sasson SC, Zaunders JJ, Zanetti G, King EM, Merlin KM, Smith DE et al. Increased plasma interleukin-7 level correlates with decreased CD127 and increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J Infect Dis 2006; 193: 505-514.
52. Rethi B, Fluur C, Atlas A, Krzyzowska M, Mowafi F, Grutzmeier S et al. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 2005; 19: 2077-2086.
53. Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S et al. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol 2005; 174: 2900-2909.
54. Boutboul F, Puthier D, Appay V, Pelle O, Ait-Mohand H, Combadiere B et al. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8T cells specific for HIV, EBV and CMV. AIDS 2005; 19: 1981-1986.
55. Carini C, McLane MF, Mayer KH, Essex M. Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur J Immunol 1994; 24: 2927-2934.
56. Wherry EJ, Day CL, Draenert R, Miller JD, Kiepiela P, Woodberry T et al. HIV-specific CD8T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory. Virology 2006; 353: 366-373.
57. + cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 cells during primary human immunodeficiency virus type 1 infection. J Virol 2006; 80: 10162-10172.
58. Fuller MJ, Hildeman DA, Sabbaj S, Gaddis DE, Tebo AE, Shang L et al. Cutting edge: emergence of CD127 high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol 2005; 174: 5926-5930.
59. Biberfeld P, Ost A, Porwit A, Sandsted B, Pallesen G, Bottiger B et al. Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol Microbiol Sect B Micobiol Immunol (Scandinavia) 1987; 95: 47-65.
60. Pallesen G, Gerstoft J, Mathiesen L. Stages of LAV/HTLV-3 lymphadenitis 1. Histological and immunological classification. Scand J Med 1987; 25: 83-91.
61. Schacker TW, Nguyen PL, Beilman GJ, Wolinsky S, Larson M, Reilly C et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110: 1133-1139.
62. Schacker TW, Brenchley JM, Beilman GJ, Reilly C, Pambuccian SE, Taylor J et al. Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13: 556-560.
63. Lempicki RA, Kovacs JA, Baseler MW, Adelsberger JW, Dewar RL, Natarajan V et al. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci USA 2000; 97: 13778-13783.
64. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5: 83-89.
65. Sachsenberg N, Perelson AS, Yerly S, Schockmel GA, Leduc D, Hirschel B et al. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 1998; 187: 1295-1303.
66. Zhang ZQ, Notermans DW, Sedgewick G, Cavert W, Wietgrefe S, Zupancic M et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: 1154-1159.
67. Fleury S, Rizzardi GP, Chapuis A, Tambussi G, Knabenhans C, Simeoni E et al. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci USA 2000; 97: 5393-5398.
68. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001; 194: 1731-1741.
69. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001; 194: 1277-1287.
70. Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Muticenter AIDS Cohort Study. Clin Immunol Immunopathol 1989; 52: 10-18.
71. Gougeon ML. Programmed cell death in HIV infection: dysregulation of BCL-2 and Fas pathways and contribution to AIDS pathogenesis. Psychoneuroendocrinology 1997; 22 (Suppl 1): S33-S39.
72. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175: 331-340.
73. Meyaard L, Otto SA, Schuitemaker H, Miedama F. Programmed cell death of T cells from human immunodeficiency virus-infected asymptomatic individuals. Science 1992; 257: 219.
74. Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000; 96: 2951-2964.
75. Boirivant M, Pica R, DeMaria R, Testi R, Pallone F, Strober W. Stimulated human lamina proria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest 1996; 98: 2616-2622.
76. de Maria R, Boirivant M, Cifone MG, Roncaioli P, Hahne M, Tschopp J et al. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. J Clin Invest 1996; 97: 316-322.
77. Scales D, Ni H, Shaheen F, Capodici J, Cannon G, Weissman D. Nonproliferating bystander CD4+ T cells lacking activation markers support HIV replication during immune activation. J Immunol 2001; 166: 6437-6443.
78. Doisne JM, Urrutia A, Lacabaratz-Porret C, Goujard C, Meyer L, Chaix ML et al. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004; 173: 2410-2418.
79. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD et al. Counting antigen-specific CD8T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-187.
80. Silvestri G, Fedanov A, Germon S, Kozyr N, Kaiser WJ, Garber DA et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol 2005; 79: 4043-4054.
81. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280: 427-431.
82. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434: 1093-1097.
83. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434: 1148-1152.
84. Gurley RJ, Ikeuchi K, Byrn RA, Anderson K, Groopman JE. CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci USA 1989; 86: 1993-1997.
85. Lane HC, Depper JM, Green WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with acquired immunodeficiency syndrome. N Engl J Med 1985; 313: 79-84.
86. Wahren B, Morfeldt-Mansson L, Biberfeld G, Moberg L, Sonnerborg A, Ljungman P et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987; 61: 2017-2023.
87. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989; 84: 1892-1899.
88. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Mann DL et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989; 339: 383-385.
89. Dyer WB, Geczy AF, Kent SJ, McIntyre LB, Blasdall SA, Learmont JC et al. Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. AIDS 1997; 11: 1565-1574.
90. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447-1450.
91. Dyer WB, Sullivan JS, Geczy AF, Learmont J, McIntyre L. Lymphoproliferative immune function in long-term survivors of transfusion acquired HIV infection. XI International Conference on AIDS, Vancouver 1996 Abstract: 65.
92. Wilson JD, Imami N, Watkins A, Gill J, Hay P, Gazzard B et al. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000; 182: 792-798.
93. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97: 3382-3387.
94. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-526.
95. Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 2049-2054.
96. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003; 198: 1909-1922.
97. Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 2004; 34: 3525-3533.
98. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005; 174: 1037-1045.
99. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5: 518-525.
100. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, Davey Jr RT et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci USA 2001; 98: 13878-13883.
101. Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP et al. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol 2003; 77: 10900-10909.
102. Boritz E, Palmer BE, Wilson CC. Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol 2004; 78: 12638-12646.
103. Palmer BE, Boritz E, Wilson CC. Effects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4+ T cell maturation and function. J Immunol 2004; 172: 3337-3347.
104. Scriba TJ, Zhang H-T, Brown HL, Oxenius A, Tamm N, Fidler S et al. HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest 2005; 115: 443-450.
105. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
106. Elrefaei M, McElroy MD, Preas CP, Hoh R, Deeks S, Martin J et al. Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol 2004; 173: 2184-2189.
107. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace II EJ, Schweighardt B et al. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr 2003; 34: 475-481.
108. Malhotra U, Holte S, Zhu T, Delpit E, Huntsbery C, Sette A et al. Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J Virol 2003; 77: 2663-2674.
109. Garcia F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15: F29-F40.
110. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163: 1220-1226.
111. Zaunders JJ, Munier ML, Kaufmann DE, Ip S, Grey P, Smith D et al. Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection. Blood 2005; 106: 1660-1667.
112. + Tcells. J Virol 2006; 80: 10151-10161.
113. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417: 95-98.
114. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
115. Nilsson J, Boasso A, Velilla PA, Zhang RM, Vaccari M, Franchini V et al. HIV-1 driven regulatory T cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006 epub; doi 10.1182/blood-2006-05-021576.
116. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200: 761-770.
117. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80: 8236-8247.
118. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77: 11708-11717.
119. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 83-92.
120. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004; 2: E20.
121. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110.
122. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655.
123. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001; 410: 980-987.
124. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991-998.
125. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998; 72: 164-169.
126. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192: 63-75.
127. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M et al. Skewed maturation of memory HIV-specific CD8T lymphocytes. Nature 2001; 410: 106-111.
128. Ellefsen K, Harari A, Champagne P, Bart PA, Sekaly RP, Pantaleo G. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. Eur J Immunol 2002; 32: 3756-3764.
129. Chen G, Shankar P, Lange C, Valdez H, Skolnik PR, Wu L et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 2001; 98: 156-164.
130. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004; 200: 701-712.
131. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3: 1061-1068.
132. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781-4789.
133. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911-4927.
134. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188: 2205-2213.
135. Tussey LG, Nair US, Bachinsky M, Edwards BH, Bakari J, Grimm K et al. Antigen burden is major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: potential implications for therapeutic immunization. J Infect Dis 2003; 187: 364-374.
136. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
137. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203: 2281-2292.
138. Trautmann L, Janbazian L, Chomont N, Said EA, Wang G, Gimmig S et al. Upregulation of PD-1 expression on HIV-specific CD8 + T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-1202.
139. Oxenius A, Sewell AK, Dawson SJ, Gunthard HF, Fischer M, Gillespie GM et al. Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. J Clin Immunol 2002; 22: 363-374.
140. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002; 99: 13747-13752.
141. Migueles SA, Connors M. Frequency and function of HIV-specific CD8(+) T cells. Immunol Lett 2001; 79: 141-150.
142. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994; 68: 8056-8063.
143. Gloster SE, Newton P, Cornforth D, Lifson JD, Williams I, Shaw GM et al. Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004; 18: 749-755.
144. Sewell AK, Price DA, Oxenius A, Kelleher AD, Phillips RE. Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape. Stem Cells 2000; 18: 230-244.
145. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354: 453-459.
146. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG, McAdam S et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995; 375: 606-611.
147. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001; 193: 181-194.
148. Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002; 76: 8690-8701.
149. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412: 334-338.
150. Navikas V, Link J, Persson C, Olsson T, Hojeberg B, Ljungdahl A et al. Increased mRNA expression of IL-6, IL10, TNF-a and perforin in blood mononuclear cells in human HIV infection. J Acq Immun Syndr Hum Retrovirol 1995; 9: 484-489.
151. Dezube BJ, Pardee AB, Beckett LA, Ahlers CM, Ecto L, Allen-Ryan J et al. Cytokine dysregulation in AIDS: in vivo overexpression of mRNA of tumor necrosis factor-alpha and its correlation with that of the inflammatory cytokine GRO. J Acquir Immun Defic Syndr 1992; 5: 1099-1104.
152. Lau AS, Williams BR. The role of interferon and tumor necrosis factor in the pathogenesis of AIDS. J Exp Pathol 1990; 5: 111-122.
153. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-1627.
154. Stone SF, Price P, Tay-Kearney ML, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002; 185: 1813-1817.
155. Stone SF, Price P, Keane NM, Murray RJ, French MA. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002; 3: 21-27.
156. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001; 184: 1073-1077.
157. El-Sadr W, Neaton J. Investigators ftSS. abstract # 106 LB: Episodic CD4-Guided Use of ART is Inferior to Continuous Therapy: results of the SMART study. Conference on Retroviruses and Opportunistic Infections. Denver, CO 2006.
158. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29: 313-319.
159. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005; 175: 2741-2753.